Ardelyx, Inc.
NASDAQ:ARDXBiotechnology
-$0.06 today
- Market cap
- $784.28M
- Beta
- 0.58
- P/E (TTM)
- -24.5
- EPS (TTM)
- -$0.24
Volume 4.75M
Average 3.58M
ARDX EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Ardelyx, Inc.NASDAQ: ARDX
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$29.77M, compared with -$33.42M a year earlier. Trailing-twelve-month EBITDA was -$25.52M.
Context
- EBITDA amounted to 7.2% of revenue in FY2025, up 2.2 pp from a year earlier.
- EBITDA grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 8 analysts of -$23.24M (+20.4%) for the fiscal year ending Dec 2026, a step up from the -74.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$29.77M-467.6% QoQ
- Last fiscal yearDec 2025
- -$29.17M-74.6% YoY
- LTMMar 2026
- -$25.52M+9.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +10.9% | +9.0% | -1.9 pp |
| 1 year | -74.6% | +20.4% | +94.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (29.17M) USD
- Year-over-year change
- -74.6%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (29.17M) | -74.6% |
| FY2024 | 2024-12-31 | (16.71M) | +69.8% |
| FY2023 | 2023-12-31 | (55.35M) | +9.2% |
| FY2022 | 2022-12-31 | (60.98M) | +59.6% |
| FY2021 | 2021-12-31 | (150.85M) | — |
EBITDA vs competitors
How ARDX compares with its peers on the latest reported figures
- ARDX's LTM Mar 2026 EBITDA of -$25.52M is the 3rd highest of the 5 companies compared; the peer median is -$20.39M.
- Its year-over-year change of +9.6% is the 2nd highest of 5, against a peer median of -125.1%.
- EBITDA amounts to 6.0% of revenue for ARDX, versus a peer median of 14.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $46.13M | +1163.1% | — | 14.7% | |
| LTM Mar 2026 | -$5.76M | -220.1% | +92.3% | 2.5% | |
| LTM Mar 2026 | -$25.52M | +9.6% | — | 6.0% | |
| LTM Mar 2026 | -$35.03M | -30.1% | — | — | |
| LTM Mar 2026 | -$119.51M | -312.9% | — | 597.6% | |
| Peer median (excluding ARDX) | -$20.39M | -125.1% | +92.3% | 14.7% | |
Competitors are the stored peer set for ARDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 10.1M | 52.16M | 124.46M | 333.62M | 407.32M |
| Cost of Revenue | 1M | 4.12M | 17.8M | 50.56M | 42.6M |
| Gross Profit | 9.1M | 48.04M | 106.66M | 283.06M | 364.72M |
| Gross Margin | 90.1% | 92.1% | 85.7% | 84.8% | 89.5% |
| Research & Development | 91.14M | 35.2M | 35.54M | 52.32M | 68.47M |
| Selling, General & Admin | 72.3M | 76.6M | 134.4M | 258.69M | 337.23M |
| Operating Expenses | 163.44M | 111.8M | 169.94M | 311.01M | 405.7M |
| Depreciation & Amortization | 2.81M | 1.14M | 1.29M | 2.06M | 3.06M |
| EBITDA | (150.85M) | (60.98M) | (55.35M) | (16.71M) | (29.17M) |
| EBITDA Margin | -1494.0% | -116.9% | -44.5% | -5.0% | -7.2% |
| Operating Income | (154.35M) | (63.76M) | (63.28M) | (27.95M) | (40.98M) |
| Operating Margin | -1528.6% | -122.2% | -50.8% | -8.4% | -10.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 4.5M | 5.07M | 8.87M | 20.09M | 28.4M |
| Other Income / Expenses | (3.82M) | (3.44M) | (2.24M) | (10.92M) | (19.65M) |
| Income Before Tax | (158.16M) | (67.2M) | (65.52M) | (38.87M) | (60.63M) |
| Pre-Tax Margin | -1566.4% | -128.8% | -52.6% | -11.7% | -14.9% |
| Income Tax Expense | 4K | 8K | 547K | 266K | 969K |
| Net Income | (158.17M) | (67.21M) | (66.07M) | (39.14M) | (61.6M) |
| Net Margin | -1566.5% | -128.9% | -53.1% | -11.7% | -15.1% |
| EPS (Basic) | (1.52) | (0.42) | (0.30) | (0.17) | (0.26) |
| EPS (Diluted) | (1.52) | (0.42) | (0.30) | (0.17) | (0.26) |
| Weighted Avg Shares | 104.21M | 158.69M | 219.33M | 235.23M | 241.03M |
| Weighted Avg Shares (Diluted) | 104.21M | 158.69M | 219.33M | 235.23M | 241.03M |
Ardelyx, Inc.
NASDAQ:ARDX
Intrinsic Alpha fair value
Locked
Current Price
$3.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.